Charta Health

The economic claim depends entirely on the model. The company is explicit that its solutions are built on large language models that read any clinical documentation, extract meaning, and run custom analysis modules per note type, drawing an explicit contrast with rules based engines relying on NLP and user generated rules. The product only exists because reviewing 100 percent of charts pre bill was previously too costly to be realistic.

The oversight model is configurable and the company says so plainly, which is the right answer for autonomous coding. It states the platform can autonomously code every note, autocorrect coding mistakes directly in the EHR, or queue problem charts for human in the loop intervention, customized to the practice's preferred level of oversight. Two supporting mechanisms matter: the AI provides direct citations to the underlying documentation so a reviewer can validate a suggestion rather than accept it blind, and coding opportunities are surfaced for simple approval or rejection.

More specific than most on approach without disclosing the stack. The company names large language models as the substrate, custom built with healthcare billing knowledge, and describes per client implementations built to replicate that client's own review criteria with an onboarding period of feedback until the AI follows their standards consistently. No model provider, evaluation methodology, or accuracy benchmark is published, and the customization model means performance is client specific rather than a single published number.

Quantified, consistent across sources, and unusually specific about the metric used. The company reports average revenue increases of roughly 11 percent measured as RVUs per patient, with a stated ceiling of 15.2 percent, and reports healthcare organizations across 43 states using the software. Naming RVUs per encounter as the measurement basis is better practice than an unqualified revenue claim. Buyers should note two things: figures are vendor reported without independent audit, and a platform whose value is measured in upcoded revenue carries an inherent tension that makes the compliance claim the one to verify hardest.

The platform reads complete clinical documentation for every encounter, so the PHI surface is total rather than sampled. The company states HIPAA, SOC 2, and GDPR compliance and offers compliance reports on request via a security contact address. The design choice that most reduces risk here is architectural rather than policy: because suggestions carry citations back to the source documentation, a fabricated or unsupported code is checkable at the point of review rather than discovered in an audit.

HIPAA compliance is stated directly in the company's published FAQ alongside SOC 2 and GDPR, with compliance reports available on request. No explicit business associate agreement commitment was located, which is the one element that would move this to an A given the platform's total access to clinical documentation.

SOC 2 and GDPR compliance are both stated, and the company publishes a route to obtain the reports by emailing its security address. That is a functioning if manual trust process. The SOC 2 type is not specified, which matters because Type 2 tests operating effectiveness over time while Type 1 assesses design at a point in time, and no self serve trust center exists.

No FDA pathway applies. The platform operates on billing and coding rather than diagnosis or treatment, and the company's own site carries a disclaimer that its clinical content and billing services are informational and not a substitute for professional medical advice. The regulatory exposure that does matter here is payer audit and False Claims Act risk attached to coding accuracy, which is a compliance regime rather than a device pathway.

No AI governance framework or bias evaluation was located. The specific governance question a buyer should press on is directional bias: a model tuned to find missed revenue has an incentive gradient toward upcoding, and while the company frames the same engine as a compliance control catching errors in both directions, no published evaluation demonstrates that the model is calibrated rather than optimized for revenue capture.

Integration is bidirectional and the write path is the point: the company states it integrates with the EHR to read all provider documentation immediately after a note closes, and can autocorrect coding mistakes directly in the EHR rather than reporting them elsewhere. It reports successful integration with dozens of commercial EHRs as well as homegrown EMRs, with a built in integration list customers select from, and assigns engineering support to each implementation. No named EHR certifications or marketplace listings were located.

No hosting, tenancy, or data residency disclosure was located. The stated GDPR compliance implies some position on European data handling, but no residency terms are published.

No published pricing. The company expresses confidence in generating positive ROI for a practice but publishes no rate, and does not disclose whether pricing is per chart, per provider, subscription, or contingent on recovered revenue. That last distinction is material in this category, since contingency pricing on found revenue creates a different incentive structure than a flat fee.

Focused on outpatient and ambulatory fee for service settings across specialties, with stated buyers including provider organizations, health systems, payers, and managed services organizations. The company positions itself for high volume lower margin specialties and cites primary care clinics operating on very thin margins as a core case, alongside an urgent care association partnership. Inpatient coding is not the target, which distinguishes it from vendors built for facility coding.